Thankyou, as always, to Josh for his thoughts.
Following a unanimous FDA advisory committee recommendation in April, the FDA has just sanctioned the U.S.’s first cannabis-derived drug, Epidiolex. This drug, containing cannabidiol( CBD) rather than marijuana’s psychoactive component (THC), will be used to calm the seizures of tens of thousands of American children affected by both Dravet syndrome and Lennox-Gastaut syndrome. However, before the drug can launch, the DEA has 90 days to make a scheduling decision.
Fox Rothschild’s Josh Horn is the co-chair of the firm’s Cannabis Law practice, and has an extensive background in several areas of legal marijuana business law. Josh has advised the Philadelphia City Council on the employment law challenges posed by Pennsylvania’s medical marijuana program as a representative of the Philadelphia Bar Association’s Medical Marijuana and Hemp Committee. Josh is a highly sought-after authority on complex cannabis law issues, and is able to provide expert commentary regarding how Canada’s new Cannabis Act how impact the United States.
Here is Josh Horn’s initial reaction to the news: “The approval of a cannabis-based drug potentially opens the door for companies who are cultivating and processing cannabis for medical purposes. I think that it is safe to say that we are going to see more companies seeking to get FDA approval for their medical cannabis products. The federal approval of a cannabis drug could be a game changer for the industry.”
Learn more about Josh’s practice at